<DOC>
	<DOCNO>NCT01223131</DOCNO>
	<brief_summary>Primary Objective : 6 To assess efficacy insulin glargine give daily ( QD ) glycosylated hemoglobin ( HbA1c ) level period 24 week child type 1 diabetes mellitus ( T1DM ) age least 6 year less 18 year . Secondary Objectives : - To assess effect insulin glargine compare NPH insulin 24 week : - Percentage patient reach International Society Pediatric Adolescent Diabetes ( ISPAD ) recommend target HbA1c &lt; 7.5 % , - Fasting blood glucose ( FBG ) , - Nocturnal blood glucose ( BG ) , - 24-hour blood glucose profile base 8-point self-monitoring blood glucose ( SMBG ) value , - Daily total insulin dose basal insulin dose , - Rates asymptomatic and/or symptomatic , severe , nocturnal nocturnal symptomatic hypoglycemia . - To assess safety tolerability insulin glargine versus NPH insulin base occurrence treatment-emergent adverse event ( TEAEs ) . - To assess anti-insulin anti-glargine antibody development group . - To assess insulin glargine pharmacokinetic ( PK ) patient treat insulin glargine select site approximately 45 % insulin glargine population rule accumulation tendency insulin glargine repeat dose</brief_summary>
	<brief_title>Efficacy Safety Insulin Glargine Versus . Neutral Protamine Hagedorn ( NPH ) Insulin Children With Type 1 Diabetes Above 6 Years Old .</brief_title>
	<detailed_description>The study duration patient 28 week +/- 7 day break follow : - Screening phase : 2 week - Run-in phase : 1 week - Treatment phase : 24 week - Follow-up : 1 week</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Protamines</mesh_term>
	<criteria>Inclusion criterion : Paediatric patient diagnose T1DM age least 6 year less 18 year screen . Exclusion criterion : Treatment oral parenteral glucoselowering medication insulin . HbA1c &lt; 7 % &gt; 12 % screening . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>